Observational Analyses of Second-Line Pharmacological Agents in Type 2 Diabetes - Cycle 2 2020

Through this initiative, PCORI seeks to fund high-quality studies using observational designs that compare the effectiveness of newer versus older second-line pharmacological agents in type 2 diabetes mellitus (T2DM) among individuals at moderate cardiovascular risk (2-3 percent risk of events per year).